[HTML][HTML] Ephrin-B2/Fc promotes proliferation and migration, and suppresses apoptosis in human umbilical vein endothelial cells

LC Zheng, XQ Wang, K Lu, XL Deng, CW Zhang… - Oncotarget, 2017 - ncbi.nlm.nih.gov
LC Zheng, XQ Wang, K Lu, XL Deng, CW Zhang, H Luo, XD Xu, XM Chen, L Yan, YQ Wang…
Oncotarget, 2017ncbi.nlm.nih.gov
Tumor growth and metastasis are angiogenesis dependent. Angiogenic growth involves
endothelial cell proliferation, migration, and invasion. Ephrin-B2 is a ligand for Eph receptor
tyrosine kinases and is an important mediator in vascular endothelial growth factor-mediated
angiogenesis. However, research offer controversial information regarding effects of ephrin-
B2 on vascular endothelial cells. In this paper, proteome analyses showed that ephrin-B2/Fc
significantly activates multiple signaling pathways related to cell proliferation, survival, and …
Abstract
Tumor growth and metastasis are angiogenesis dependent. Angiogenic growth involves endothelial cell proliferation, migration, and invasion. Ephrin-B2 is a ligand for Eph receptor tyrosine kinases and is an important mediator in vascular endothelial growth factor-mediated angiogenesis. However, research offer controversial information regarding effects of ephrin-B2 on vascular endothelial cells. In this paper, proteome analyses showed that ephrin-B2/Fc significantly activates multiple signaling pathways related to cell proliferation, survival, and migration and suppresses apoptosis and cell death. Cytological experiments further confirm that ephrin-B2/Fc stimulates endothelial cell proliferation, triggers dose-dependent migration, and suppresses cell apoptosis. Results demonstrate that soluble dose-dependent ephrinB2 can promote proliferation and migration and inhibit apoptosis of human umbilical vein endothelial cells. These results also suggest that ephrinB2 prevents ischemic disease and can potentially be a new therapeutic target for treating angiogenesis-related diseases and tumors.
ncbi.nlm.nih.gov